DexCom Inc. (NASDAQ:DXCM) introduced new long-term financial targets during its 2026 Investor Day, outlining expectations for sustained revenue growth and stronger profitability through the end of the decade.
Company Highlights Long-Term Margin Expansion Goals
The diabetes technology company in an SEC filing said it expects organic revenue growth of more than 10% annually through 2030.
DexCom also projected a 2030 adjusted gross profit margin between 67% and 69%.
In addition, the company forecasts an adjusted operating profit margin of 29% to 30% by 2030, along with an adjusted EBITDA margin of 36% to 37%.
